Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Survodutide: Evidence Summary
Evidence summary for Survodutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Survodutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Obesity / weight management | Tier B | 5 | Phase 3 complete showing 15-20% weight loss; FDA submission pending |
| Type 2 diabetes (glycemic control) | Tier B | 3 | Phase 3 complete showing 1.3% HbA1c reduction; not yet approved |
| MASLD / liver fat reduction | Tier C | 1 | Phase 2 showed 30% liver fat reduction; registration trial needed |
| Cardiovascular risk reduction | Tier D | 0 | CVOT ongoing; outcomes data expected 2027-2028 |
References (3)
- Survodutide Phase 2 trial in obesity and type 2 diabetes — Nauck MA, et al. . Lancet (2023) PMID: 41054801
- Survodutide Phase 2 trial for liver fat reduction in MASLD — Sanyal AJ, et al. . New England Journal of Medicine (2024) PMID: 38847460
- Systematic review of dual GLP-1/glucagon receptor agonists — Various . Diabetes, Obesity and Metabolism (2024) PMID: 36050763